Month: May 2022

Actelis Networks, Inc. Announces Pricing of its Initial Public Offering

Written by Customer Service on May 13, 2022. Posted in Public Companies.

FREMONT, Calif., May 13, 2022 (GLOBE NEWSWIRE) — Actelis Networks, Inc. (NASDAQ:ASNS) (“Actelis” or the “Company”), a provider of cyber-hardened, rapid-deployment networking solutions for wide-area IoT networks, today announced the pricing of its initial public offering of 3,750,000 shares of its common stock (the “Common Stock”) at a public offering price of $4.00 per share, for aggregate gross proceeds of $15.0 million, prior to deducting underwriting discounts, commissions, and other offering expenses. Boustead Securities, LLC (“Boustead”) is acting as the sole underwriter for the offering. The shares of Common Stock are expected to begin trading on The Nasdaq Capital Market as of today, May 13, 2022, under the symbol “ASNS”. In addition, the Company has granted Boustead, which acted as the sole underwriter for the offering,...

Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products

Written by Customer Service on May 13, 2022. Posted in Public Companies.

Statera expects to acquire option to license Lay Sciences products for respiratory & gastrointestinal disorders FORT COLLINS, Colo., May 13, 2022 (GLOBE NEWSWIRE) — Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Company intends to enter into a non-binding term sheet with respect to a strategic partnership with Lay Sciences, Inc. (“Lay Sciences”), a development and commercialization company of innovative solutions, to license worldwide manufacturing rights to certain Lay Sciences’ IgY products containing avian antibodies as an active ingredient. “The strategic partnership with Lay Sciences has the potential to produce near term revenue,” said Michael K. Handley, President and Chief...

Invesco Ltd.: Form 8.3 – Capital & Counties Properties PLC CORRECTION

Written by Customer Service on May 13, 2022. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1. KEY INFORMATION (a) Full name of discloser: Invesco Ltd. (b) Owner or controller of interests and short positions disclosed, if different from 1(a):The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates:Use a separate form for each offeror/offeree Capital & Counties Properties plc (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken:For an opening position disclosure, state the latest practicable...

Ceylon Graphite Closes Upsized $3,500,000 Private Placement and Extension of Debentures

Written by Customer Service on May 13, 2022. Posted in Public Companies.

VANCOUVER, May 13, 2022 (GLOBE NEWSWIRE) — Ceylon Graphite Corp. (“Ceylon” or the “Company”) (TSXV: CYL) (OTCQB: CYLYF) (FSE: CCY) is pleased to announce that further to its press releases of April 6 and 7, 2022, it has closed a private placement of 21,875,000 units (“Units”) at a price of $0.16 per Unit for gross proceeds of $3,500,000 (the “Offering”). Each Unit consists of one common share in the capital of the Company (“Share”) and one common share purchase warrant (“Warrant”). Each Warrant entitles the holder thereof to acquire one common share of the Company (each a “Warrant Share”) at a price of $0.25 per Warrant Share at any time until May 10, 2025. Ceylon intends to use the net proceeds of the Offering to advance the Company’s K1 and M1 mines to commercial production. The Company anticipates achieving this milestone within...

HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights

Written by Customer Service on May 13, 2022. Posted in Earnings Releases And Operating Results.

MIRAMAR, Fla., May 13, 2022 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2022. “We continue to successfully execute our clinical development strategy which is based on our unique approach toward inflammaging,” stated Hing C. Wong, Founder and CEO of HCW Biologics Inc. “HCW Biologics is developing immunotherapeutics that do not treat a single indication or symptom. Our approach is to treat a patient systemically to remove the underlying problems causing a condition.” Dr. Wong continued, “Our...

Condor Gold plc announces its unaudited results for the three months ended 31 March 2022

Written by Customer Service on May 13, 2022. Posted in Earnings Releases And Operating Results.

Condor Gold Plc (“Condor Gold”, “Condor” or the “Company”) LONDON, May 13, 2022 (GLOBE NEWSWIRE) — Condor Gold (AIM: CNR; TSX: COG) announces that it has today published its unaudited financial results for the three months ending 31 March 2022 and the Management’s Discussion and Analysis for the same period. Both of the above have been posted on the Company’s website www.condorgold.com and are also available on SEDAR at www.sedar.com. Highlights for the First Quarter of 2022:On March 10, 2022, the Company announced that all assay results have been received for an 8,004 m infill drilling programme on the fully permitted high-grade La Mestiza Open Pit Mineral Resource at La India Project. Advanced the technical studies needed for the completion of a Definitive Feasibility Study covering the La India open pit, the processing plant...

Adagio Therapeutics Reports First Quarter 2022 Financial Results

Written by Customer Service on May 13, 2022. Posted in Earnings Releases And Operating Results.

$532.2 Million in Total Cash at Quarter End; Strong Balance Sheet Expected to Support Operations into Second Half of 2024 Additional Data from Adintrevimab Phase 2/3 STAMP Treatment Trial to be Presented at ASM Annual Meeting WALTHAM, Mass., May 13, 2022 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases, today reported financial results for the quarter ended March 31, 2022. “We continue to be encouraged by adintrevimab’s potential as a prophylactic and treatment option for certain variants of SARS-CoV-2, which is supported by the positive data that met all primary endpoints from our global EVADE and STAMP trials. We continue to engage with the FDA and are closely monitoring...

Embecta Corp. Reports Second Quarter and First Six Months of Fiscal Year 2022 Financial Results and Provides Financial Guidance for the Last Six Months of Fiscal Year 2022

Written by Customer Service on May 13, 2022. Posted in Earnings Releases And Operating Results.

PARSIPPANY, N.J., May 13, 2022 (GLOBE NEWSWIRE) — Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world following its April 1, 2022, spin off from Becton, Dickinson and Company (“BD”), today reported financial results for the three- and six-month periods which ended March 31, 2022, and provided financial guidance for the last six months of the fiscal year ending September 30, 2022. “Our global team successfully executed the spin off from BD while meeting our commitments and maintaining the high level of service that our customers and the millions of people with diabetes that use our products deserve and expect,” said Devdatt “Dev” Kurdikar, Chief Executive Officer of embecta. “Listing the independent company’s stock on Nasdaq on April 1 was an inspiring and unifying...

The Honest Company Reports First Quarter 2022 Results In Line With Outlook

Written by Customer Service on May 13, 2022. Posted in Earnings Releases And Operating Results.

Maintains Full Year 2022 OutlookContinues to Forecast Growth for the Remainder of the Fiscal YearPlans for Pricing Execution, Innovation, and New Retail Distribution Remain on Track LOS ANGELES, May 13, 2022 (GLOBE NEWSWIRE) — The Honest Company (NASDAQ: HNST), a digitally native, mission-driven brand focused on leading the clean lifestyle movement, today reported financial results for the three months ended March 31, 2022. “In the face of significant macro headwinds, I’m pleased we are able to maintain our financial outlook for the year. Consistent with the expectations we communicated on our last earnings call, the first quarter of 2022 experienced challenging comparisons year-over-year as well as softness in the digital space as many consumers returned to in-store shopping in our product categories. With the first quarter behind...

PLx Pharma Inc. Reports First Quarter 2022 Results and Provides Business Update

Written by Customer Service on May 13, 2022. Posted in Earnings Releases And Operating Results.

BUILDING A SOLID BASE OF VAZALORE® USERSTotal Net Sales of $2.1 Million in the First Quarter of 2022, an Increase of Approximately 31% from Fourth Quarter of 2021 GAAP Net Loss of ($0.39) Per Diluted Share in the First Quarter 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.66) Cash & Cash Equivalent Balance of $52.5 Million as of March 31, 2022 Disciplined Spending to Support Strategic GrowthSPARTA, N.J., May 13, 2022 (GLOBE NEWSWIRE) — PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products...

Month: May 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals